CORPORATE SUPPORTERS

ASFA wishes to acknowledge the support of all companies and organizations that contributed generously to the ASFA 2024 Annual Meeting.

GOLD LEVEL SUPPORTERS:

BRONZE LEVEL SUPPORTER:

SYMPOSIA AND FOCUS GROUP SUPPORTERS:
WEDNESDAY, APRIL 17, 2024

8:00AM – 4:30PM Exhibit Hall Move In

12:00PM – 1:00PM
Corporate Lunch Symposium
(Lotus Ballroom)
Outcomes of Treatment with CABLIWI (caplacizumab-yhdp)
Join us for an engaging discussion on aTTP/iTTP and available treatment options for the disease.

Learning Objectives:
• Provide an overview of aTTP/iTTP, including pathophysiology, epidemiology, patient presentation, disease burden, and diagnosis
• Understand the importance of rapid diagnosis and immediate treatment due to acute nature and high mortality of aTTP/iTTP disease if left untreated
• Discuss available treatment options for aTTP/iTTP
• Review results of US and international real-world studies on aTTP/iTTP
• Review the ISTH Guidelines and their recommendation on Diagnosis and Treatment Approaches for TTP.
• Discuss coverage and reimbursement for CABLIWI.
• Q&A Session

Dr. Gustaaf de Ridder, MD, PhD, System Director of Transfusion Services and Director of Apheresis and Patient Blood Management at Geisinger Health System in Pennsylvania.

Leticia Gonzalez, Director of Institutional Accounts Teams at Sanofi.

6:00PM – 8:00PM Welcome Reception in Exhibit & Poster Hall

THURSDAY, APRIL 18, 2024

10:00AM – 6:30PM Exhibit & Poster Hall Open

10:15AM – 10:45AM Break in Exhibit & Poster Hall

12:30PM – 1:30PM
Corporate Lunch Symposium
(Lily Ballroom A, D)
Advances in iTTP management – Contemporary Clinical Approaches
Gain insights from a panel of experts on why and how to prioritize clinical management of Immune thrombotic thrombocytopenic purpura (aTTP/iTTP), focusing on early treatment, and achieving durable responses from therapies, ultimately resulting in improved clinical outcomes.

The symposium will be presented in two parts:
• Part 1 will illustratively describe the iTTP pathophysiology, epidemiology/diagnostic considerations, burden of disease, facets of pathology and corresponding treatment axes, before discussing the ISTH guidelines on diagnosis and treatment of iTTP.
• Part 2 will review the rationale and the recently revised iTTP outcome definitions (clinical response, exacerbation, remission, and relapse) by the International Working Group (IWG 2021), the important implications on clinical management of iTTP, and finishing with two case vignettes to understand real-world application of these new practices.

Please join our Sanofi Medical Affairs Rare Blood Disorders team for our medical symposium led by:

Dr. Minh-Ha Tran, DO, Clinical Professor at the Department of Pathology & Laboratory Medicine, and Medical Director of the UCI Transfusion Medicine Service, UC Irvine Medical Center.

Dr. Jeffrey Laurence, MD, Professor of Medicine in the Division of Hematology-Oncology at Weill Cornell Medicine/New York Presbyterian, and attending physician at the Center for Blood Disorders at New York
**Corporate Lunch Symposium**

(Collection of MNCs with the Amicus Separator for downstream CAR-T Manufacturing)

*Collection of MNCs with the Amicus Separator for downstream CAR-T Manufacturing*

**Learning Objectives:**
- Understand a new transfer state for mononuclear cell harvest available in Amicus Separator software version 6.1 and how it impacts collection efficiency
- Describe interim results of a retrospective study comparing MNC collection efficiency using Amicus Separator software versions 6.0 and 6.1
- Explore the considerations associated with collecting MNCs for CAR-T manufacturing in pediatric patients, including instrumentation settings, and adverse events
- Gain insights into the practical implications of utilizing the Amicus Separator for MNC collection for downstream CAR-T manufacturing

**Miquel Lozano, MD, PhD**
Hospital Clinic Barcelona, Spain, Chief, Hemotherapy Section, Department of Hemotherapy and Hemostasis, Associate Professor of Medicine, University of Barcelona

**Volker Witt, MD**
St. Anna Kinderspital, Vienna, Austria, Head, Pediatric Apheresis Unit, Commissioner of Blood & Tissue Bank

---

**FRIDAY, APRIL 19, 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00am – 4:30pm</td>
<td>Exhibit &amp; Poster Hall Open</td>
<td>Lily Ballroom B, E, G, H</td>
</tr>
<tr>
<td>10:15am – 10:45am</td>
<td>Break in Exhibit &amp; Poster Hall</td>
<td>Lily Ballroom B, E, G, H</td>
</tr>
<tr>
<td>12:30pm – 1:30pm</td>
<td>Lunch</td>
<td>Pre-Function</td>
</tr>
<tr>
<td>3:30pm – 4:00pm</td>
<td>Break in Exhibit &amp; Poster Hall</td>
<td>Lily Ballroom B, E, G, H</td>
</tr>
<tr>
<td>4:30pm – 8:00pm</td>
<td>Exhibit Hall Move Out</td>
<td>Lily Ballroom B, E, G, H</td>
</tr>
</tbody>
</table>
Corporate Program

April 17-19, 2024, Las Vegas, NV

Exhibitor Floorplan

Booth #  Company
12  Alexion, AstraZeneca Rare Disease Unit
11  BD
16  Bel Air Pharmaceuticals
14  BioLineRx USA, Inc
21  DMMED Group
18  Foundation for the Accreditation of Cellular Therapy
7, 8  Fresenius Kabi
19  ICCBBA

Booth #  Company
5  Kaneka Medical America, LLC
1  Mallinckrodt Pharmaceuticals
4  MEDICA SPA
13  Miltenyi Biotec B.V. & Co. KG
10  NMDP
15  Sanofi
2, 3  Terumo Blood and Cell Technologies
20  UC San Diego Health
17  University of Virginia
EXHIBITORS

ALEXION, ASTRAZENECA RARE DISEASE UNIT

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

BEL AIR PHARMACEUTICALS

Bel Air Pharmaceuticals is a research-based biopharmaceutical company headquartered in Fort Lauderdale, FL. We provide therapies to address unmet patient needs. For over 22 years we have been using our experience and expertise, focused on our mission: to discover new ways to improve people’s lives around the world.

BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. bd.com

BIOLINERX

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company’s first approved product is APHEXDA® (motixafortide) with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma. BioLineRx is advancing a pipeline of investigational medicines for patients with sickle cell disease, pancreatic cancer, and other solid tumors. Headquartered in Israel, and with operations in the U.S., the company is driving innovative therapeutics with end-to-end expertise in development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

Learn more about who we are, what we do, and how we do it at www.biolinerrx.com, or on Twitter and LinkedIn.
Our company supplies medical products as a first aid, dermatology supply, medical equipment care and much more.

**FRESENIUS KABI**

Fresenius Kabi is a health care company specializing in life-saving medicines and technologies. Known as a leader in transfusion medicine, the company offers a comprehensive portfolio of medical technologies for therapeutic apheresis and blood collection.

**FOUNDATION FOR THE ACCREDITATION OF CELLULAR THERAPY**

FACT is a non-profit corporation founded for the purpose of voluntary inspection and accreditation in the field of cellular therapy, cord blood banking, and regenerative medicine. The objective of FACT is to improve the quality of cellular therapy through peer-developed standards, education and accreditation for the benefit of patients.

The Foundation for the Accreditation of Cellular Therapy (FACT) is the standards setting and accreditation arm of the International Society for Cellular Therapy (ISCT) and the American Society of Blood and Marrow Transplantation (ASBMT), founded to improve the quality of hematopoietic progenitor cell transplantation, cord blood banking and cellular therapies. The FACT mission is accomplished through peer-developed standards, professional education, and voluntary accreditation for the benefit of patients worldwide.

**ICCBBA**

ICCBBA is the not-for-profit, nongovernmental international standards organization responsible for the management and development of the ISBT 128 Standard. Used in more than 85 countries across six continents and disparate health care systems, ISBT 128 is the global standard for the terminology, identification, coding, and labeling of medical products of human origin including blood, cell, tissue, milk, and organ products. The Standard has been designed to ensure the highest levels of accuracy, safety, and efficiency for the benefit of donors and patients worldwide.

**KANEKA**

Kaneka Medical America (KMA) is a wholly owned subsidiary of Kaneka Americas Holdings, Inc. Established in 1997, KMA, with main office located in New York, NY, is the exclusive distributor in the U.S. and Canada for the extracorporeal Lipoprotein Apheresis system, LIPOSORBER®, manufactured by Kaneka Corporation. It is the only Lipoprotein Apheresis therapy approved by FDA for the following two patient populations:

1. Clinically diagnosed Familial Hypercholesterolemic patients with either documented CAD or PAD, if LDL-C > 100mg/dl or Lp(a) > 60 mg/dl and LDL-C > 100 mg/dl when diet and maximum tolerable combination lipid-lowering drug therapies have failed to achieve the established therapeutic targets per professional guidelines.

2. Adult and pediatric patients with nephrotic syndrome associated with primary FSGS when:
   - Standard treatment options, including corticosteroids and/or calcineurin inhibitor treatments, are unsuccessful or not well tolerated and the patient’s GFR > 60 ml/min/1.73 m²
   - The patient is post renal transplantation
Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company’s Specialty Brands reportable segment’s areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

The Medica Group has been operating in Mirandola’s biomedical district since 1985. Innovation and the development of new products for blood purification have always been at the core of the company’s business. Thanks to the work of two extremely dynamic R&D groups (electromedical equipment, membranes and disposables) and the transversal synergies between all the companies in the group, Medica has successfully established itself in the main international markets, which are now represented by the company’s three Business Units:

- Medical division (Dialysis, CRRT, Apheresis, Cardiology, Oncological Surgery, Organ Transplantation, Bio-regenerative Medicine, Urology and Gastroenterology Diagnostics, Oxygen humidification)
- Microbiological water purification (ultrafiltration and microfiltration)
- Turnkey solutions for the design and development of custom products (OEMs), electromedical devices, disposable medical devices, membranes or filters, as well as the development of the automation technologies required for their production and testing.

The main success factors of the Medica Group are:

- The extrusion of hollow fibre membranes;
- The Group’s vertical integration;
- The vocation to export with sales in over 60 countries including Europe, the USA and China.

MedSol has maintained its mission of providing clinically superior products that demonstrate proven advantages in quality, efficiency, safety, and overall cost effectiveness either with our exclusive distribution partners or through our own branded portfolio.

MedSol can meet your needs for sales and support wherever you are located through our direct sales representatives, our network of excellent distributors in select territories in the United States, as well as our international partners worldwide. We offer our products in all 50 states and world-wide through our international partners.

Our Mission: We embrace the changing healthcare environment and endeavor to go the extra mile for our customers and stakeholders, making technology more friendly to people and offer competent flexible and reliable quality services, supporting diagnostic confidence, we insist on the utmost in quality of products, we commit to strengthen our position as a market leader, acting in harmony with sincerity and assuming social responsibility.

Our Vision: To provide quality products, be a model health system by providing products to improve the quality of life.

Milttenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level,
from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.

NMDP

At NMDP, we believe each of us holds the key to curing blood cancers and disorders. As a global nonprofit leader in cell therapy, NMDP creates essential connections between researchers and supporters to inspire action and accelerate innovation to find life-saving cures. With the help of blood stem cell donors from the world’s most diverse registry and our extensive network of transplant partners, physicians, and caregivers, we’re expanding access to treatment so that every patient can receive their life-saving cell therapy. NMDP. Find cures. Save lives.

SANOFI

Sanofi’s global specialty care business unit focuses on rare diseases, rare blood disorders, neurology, immunology, and oncology leveraging science and innovation to help improve people’s lives. www.sanofi.us

TERUMO BLOOD AND CELL TECHNOLOGIES

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. TERUMOBCT.COM

UC SAN DIEGO HEALTH

Essentials and Advances in Apheresis Therapies Conference in San Diego, California is designed to appeal to first time attendees and to returning participants. Expert reviews of the essentials will be augmented with selected new topics and discussions of advances and innovations.

- Nationally and internationally recognized leaders will present didactic sessions and conduct interactive discussions.
- Fundamentals include in-depth reviews of basic principles, procedures, prescribing, clinical management and care of special populations.
- Updates on selected disease indications supplemented by case studies and new clinical science.
- Review plasma exchange, cell apheresis modalities, technology innovations, and program management.
- Popular sessions on Frontiers in Apheresis Science and Expertise in Apheresis Practice will continue with updated topics.
- Participants will be offered small group sessions led by experienced practitioners demonstrating various techniques and machines used in therapeutic apheresis.
- Conference attendees can submit challenging cases for discussion during an expert panel session.
The 16th Annual Therapeutic Apheresis Academy is a comprehensive 2 ½ day multidisciplinary course that aims to enhance interprofessional learning through modern teaching methods. The general session will cover current practices, recent updates, and strategies for establishing new therapeutic apheresis services. Demonstration workshops will offer hands-on clinical applications and insights from seasoned practitioners. Our lineup features nationally and internationally recognized experts in apheresis, along with experienced frontline clinical practitioners.

This conference is designed for physicians, nurses, and other allied health professionals in the fields of nephrology, hematology, pathology/blood banking, and neurology, who specialize in therapeutic apheresis and provide care for both adult and pediatric patients.

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia and continues to advance its research in these diseases. Vertex has a broad and deep clinical pipeline across a range of modalities for other serious diseases like type 1 diabetes, APOL1-mediated kidney disease and pain.
Don’t let cell collection challenges get in the way of achieving your targets

With over 40 years’ experience and expertise in apheresis, we are positioned to help you master the challenges of cell collection. Learn the fundamentals of cell collection requirements and the significance of high-quality starting material for consistent and predictable procedures.

Download our white paper and visit our booth for more.
Apply to become a FACT INSPECTOR
Cellular Therapy • Cord Blood Banking • Immune Effector Cell

Contribute to Standards Development

Exposure to Exemplary Practices

Professional Development

Free Access to Educational Resources

Are you ready?
Scan the QR code or visit https://www.factglobal.org/inspectors

OUR PURPOSE
Optimize patient care and access to cellular therapy by providing an unbiased and unified auditing system applicable to quality, operational, and regulatory requirements of any stakeholder.

A PROVEN PROCESS
Leverage comprehensive methods based on the most trusted, global accreditation program in cellular therapy:

- Checklist-based tracing methodology
- Adaptability to evolving science and environments
- Guidance toward correction of observations

ASSessment OFFerings
☐ Quality Systems Verification
☐ Site Qualification
☐ Surveillance/Monitoring Audits
☐ Ad Hoc/For Cause Audits

CONTACT US
consulting@factglobal.org

APHERESIS AWARENESS DAY®
TUESDAY, SEPTEMBER 17, 2024

ASFA is excited to announce this special occasion and invites you to participate on Tuesday, September 17th, 2024, and throughout the entire month of September. Discover the various ways you can get involved and show your support for this important cause. Don’t miss out on the opportunity to make a difference and help raise awareness about apheresis.

SUPPORT THE CELEBRATION
As a sponsor, you will have the opportunity to engage directly with apheresis leaders through our virtual platform and forge valuable professional relationships with experts in apheresis, blood banking, transfusion medicine, and cellular therapy.

#AAD2024 #apheresisd2024
SAVE THE DATE

ASFA 25
Montreal • Canada • April 9-11, 2025

EARN CME, CMLE, & CEU CREDITS
An Educational and Networking Forum For Professionals in the Field of Apheresis Medicine

PROGRAM FORMAT:
- Scientific Symposia
- Education Sessions
- Oral & Poster Presentations
- Interactive Case Studies & Discussion
- Receptions
- Committee Meetings
- Corporate Symposia & Focus Groups
- Exhibit Hall
- Apheresis Review Session

- PROPOSE A SESSION
- RECOMMEND A SPEAKER
- SUBMIT AN ABSTRACT
- REGISTER TO ATTEND
- RESERVE YOUR EXHIBIT SPACE
- BOOK YOUR CORPORATE SYMPOSIUM OR FOCUS GROUP

ASFA 2025 CONFERENCE SECRETARIAT
Malachite Management Inc
1618 Station St, Vancouver, BC, Canada V6A 1B6
T. 604.484.2851 F. 604.874.4378
Email: asfa@apheresis.org Web: www.apheresis.org